Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
The Vanguard Group has become a substantial holder in Mesoblast Limited, acquiring a 5.004% voting power with 63,941,083 ordinary shares. This significant investment by a major global asset manager could enhance Mesoblast’s market credibility and attract further interest from investors, potentially impacting its stock performance and strategic positioning in the biotechnology sector.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.30 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company specializes in regenerative medicine, targeting conditions such as heart failure, chronic low back pain, and inflammatory diseases.
Average Trading Volume: 6,509,623
Technical Sentiment Signal: Hold
Current Market Cap: A$2.06B
See more insights into MSB stock on TipRanks’ Stock Analysis page.